Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 | Q9Y3Q4 | 7/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CCL2 | P13500 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15858419 | 1.00 | HCN4 (0.64) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL30284992 | 1.00 | HCN4 (0.64) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL31280 | 1.00 | HCN4 (0.64) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Hydrochloric Acid SCHEMBL14696912 | 0.99 | HCN4 (0.63) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Oxalic Acid SCHEMBL2594323 | 0.95 | HCN4 (0.59) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Oxalic Acid SCHEMBL2594327 | 0.95 | HCN4 (0.59) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL10022907 | 0.95 | HCN4 (0.58) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL16203194 | 0.94 | HCN4 (0.60) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Nitric Acid SCHEMBL2594562 | 0.94 | HCN4 (0.57) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Nitric Acid SCHEMBL2594567 | 0.94 | HCN4 (0.57) | HCN4CHRM2HTR1ASLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014020534-A1 | IVABRADINE HYDROCHLORIDE AND THE PROCESSES FOR PREPARATION THEREOF | BIOCON LIMITED (IN) | 2014-02-06 | — | — | WO | claimed |
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | disclosed |
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017138017-A1 | PROCESS FOR THE PREPARATION OF BENZAZEPINE-2-ONE DERIVATIVE | IND-SWIFT LABORATORIES LIMITED (IN) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017021466-A1 | A PROCESS FOR PREPARATION OF SOLID IVABRADINE HYDROCHLORIDE | SYNTHON B.V. (NL) | 2017-02-09 | — | — | WO | disclosed |
| US-8779123-B2 | Process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| WO-2014020534-A1 | IVABRADINE HYDROCHLORIDE AND THE PROCESSES FOR PREPARATION THEREOF | BIOCON LIMITED (IN) | 2014-02-06 | — | — | WO | disclosed |
| US-8415468-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-04-09 | — | — | US | disclosed |
| EP-2566850-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE SALTS | Richter Gedeon Nyrt. (HU) | 2013-03-13 | — | — | EP | disclosed |
| EP-2202225-B1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | SERVIER LAB (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-8097720-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | Les Laboratories Server (FR) | 2012-01-17 | — | — | US | disclosed |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2011-12-01 | — | — | US | disclosed |
| WO-2011138625-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE SALTS | RICHTER GEDEON NYRT. (HU) | 2011-11-10 | — | — | WO | disclosed |
| EP-2202225-A1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.